“The European Medicines Agency might supplant the FDA as the gold standard if the FDA goes off track and is politically ...

The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...

Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...

Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ... Read ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

The FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...

Modern pharmaceuticals have revolutionised disease prevention and treatment. But eventually, the chemicals can end up in rivers, oceans and soils.

BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...

China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western ...